EU/3/15/1531
Table of contents
About
On 28 July 2015, orphan designation (EU/3/15/1531) was granted by the European Commission to Newron Pharmaceuticals SpA, Italy, for sarizotan hydrochloride for the treatment of Rett syndrome.
Key facts
Active substance |
Sarizotan hydrochloride
|
Disease / condition |
Treatment of Rett syndrome
|
Date of first decision |
28/07/2015
|
Outcome |
Positive
|
EU designation number |
EU/3/15/1531
|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor's contact details
Newron Pharmaceuticals SpA
Via Lodovico Aristo
20091 Bresso
Milan
Italy
Tel. +39 0261034622
Fax +39 0261034654 or +39 0261034655
E-mail: info@newron.com
Via Lodovico Aristo
20091 Bresso
Milan
Italy
Tel. +39 0261034622
Fax +39 0261034654 or +39 0261034655
E-mail: info@newron.com
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.